20 Nonsense suppressors (NonSups) treat premature termination codon (PTC) disorders by inducing 21 the selection of near cognate tRNAs at the PTC position, allowing readthrough of the PTC and 22 production of full-length protein. Studies of NonSup-induced readthrough of eukaryotic PTCs 23
Introduction 34
Premature termination codons (PTCs) arise as a consequence of nonsense mutations and 35 lead to the replacement of an amino acid codon in mRNA by one of three stop codons, UAA, UGA 36 or UAG (Brenner, et al., 1965; Shalev and Baasov, 2014; Keeling, et al., 2014) , resulting in 37 inactive truncated protein products. Nonsense mutations constitute ~20% of transmitted or de novo 38 germline mutations (Salvatori, et al., 2009; Goldmann, et al., 2012; Stenson, et al., 2017) . Globally, 39
there are ~7000 genetically transmitted disorders in humans and ~11% of all human disease 40 mutations are nonsense mutations (Loudon, 2013) . Clearly, millions of people worldwide would 41 benefit from effective therapies directed toward PTC suppression. Clinical trials have begun to 42 evaluate the treatment of PTC disorders with therapeutic agents called nonsense suppressors 43 (NonSups) (Peltz, et al., 2013; McDonald, et al., 2017; Zainal Abidin, et al., 2017) . NonSups 44 induce the selection of near cognate tRNAs at the PTC position, and insertion of the corresponding 45 amino acid into the nascent polypeptide, a process referred to as "readthrough", which restores the 46 production of full length functional proteins, albeit at levels considerably reduced from wild-type. suggest that NonSups having DIRECT-NSIRT effects can be divided into at least two distinctive 80 structural groups that induce nonsense suppression by different mechanisms. We also demonstrate 81 the potential of using single molecule fluorescence resonance energy transfer (smFRET) 82 experiments to elucidate the details of such mechanisms. 83 84
Materials and Methods 85
Nonsense suppressors (Figure 1 ). The following NonSups were obtained from commercial sources: 86 gentamicin mixture and G418 (Sigma), nourseothricin sulfate, a mixture of streptothricins D and 87 F (Gold Biotechnology), doxorubicin (Fisher Scientific), escin and tylosin (Alfa Aesar), 88 azithromycin (APExBIO). Gentamicins B and B1 were prepared as described (Baradaran-Heravi, 89 et al., 2017). PTC Therapeutics supplied the following NonSups: ataluren sodium salt, RTC13, 90 GJ071, GJ072, and gentamicin X2. Negamycin was a gift from Alexander Mankin, University of 91 two centrifugations at 30,000 x g for 15 min at 4°C. 80S ribosomes in the supernatant were 102 precipitated by adding 175 mL of 4.5% PEG 20k (Ben-Shem, et al., 2011) and resuspended in 60 103 mL of dissociation buffer 1 (20 mM HEPES-KOH, pH 7.5, 500 mM KCl, 2 mM MgCl 2 , 6.8% 104 sucrose 2 mM DTT, 1:1000 RNasin, 2 protease minitablets). Puromycin was added to a final 105 concentration of 2 mM, and the resulting solution was incubated on ice for 30 min, then at 37 °C 106 for 15 min. 40S and 60S subunits (approximately 6,000 A 260 units) were then resolved by a 10-107 30% hyperbolic sucrose gradient centrifugation for 16 h in a Beckman Ti15 zonal rotor at 376,000 108
x g in dissociation buffer 2 (20 mM HEPES, pH 7.5, 0.5 M KCl, 5 mM MgCl 2 , 3 mM EDTA, 2 109 mM DTT) at 4 o C. Carrier 70S ribosomes were isolated from S30 of E. coli cells by three 110 consecutive ultracentrifugations through a 1.1 M sucrose cushion in a buffer of 20 mM Tris, pH 111 7.5, 500 mM NH 4 Cl, 10 mM Mg Acetate, 0.5 mM EDTA, 3 mM 2-mercaptoethanol. Elongation 112 factors eEF2 and eEF1A (Thiele, et al., 1985) were isolated from Baker's 113 yeast as described. Yeast 6xHis-tagged release factors (full-length eRF1 and amino acids 166-685 114 of eRF3) were expressed in E. coli and purified using a TALON cobalt resin. Both release factors 115 were a generous gift from Alper Celik (University of Massachusetts Medical School). 116 117 tRNA and mRNA. tRNA Lys , tRNA Val , tRNA Gln , and tRNA Met were isolated from E. coli bulk tRNA 118 (Roche). tRNA Arg , tRNA Trp and tRNA Leu were isolated from Baker's yeast bulk tRNA (Roche), 119 using hybridization with immobilized complementary oligoDNA as described previously 120 (Barhoom, et al., 2013; Liu, et al., 2014) . Yeast tRNA Phe (Sigma) and all isoacceptor tRNAs 121 mentioned above where charged with their cognate amino acids as described (Pan, et al., 2007; 122 Pan, et al., 2009 ). CrPV-IRES (Zhang, et al., 2016) was modified by Genscript, Inc to encode the 123 initial mRNA sequence UUCAAAGUGAGAUGGCUAAUG (denoted Trp-IRES). A point 124 mutation was introduced into Trp-IRES to convert the UGG codon for Trp into a UGA stop codon 125 Trp-tRNA Trp by added organic solvent (Table S1 ) was additionally subtracted as background. 169
Readthrough levels presented in Figures 3 and S3 are all background subtracted. Although PEP-170
Quant has a lower procedural background, it is time consuming to perform, and less precise than 171 tRNA-Quant. Both assays show a basal level of readthrough, in the absence of added NonSup, of 172 0.08 ± 0.02 (sd, n=40) octapeptide/POST5 above background, with some day-to-day variation. to make a PRE6 complex. Unbound Trp-TC(Cy3) was washed out of the channel with Buffer 4 184 containing a deoxygenation enzyme system of 100 µg/mL glucose oxidase, 3 mg/mL glucose, and 185 48 µg/mL catalase to minimize photobleaching. Cy3 and Cy5 fluorescence intensities were 186 collected with 100 ms time resolution using alternating laser excitation (ALEX) between 532 nm 187 and 640 nm lasers on an objective-type total internal reflection fluorescence microscope described 188 previously (Chen, et al., 2011) . For experiments measuring both PRE6 complex and POST6 189 complex formation, Trp-IRES-PRE6 complex was formed as described above and 1 μM eEF-2 190 was injected while recording the FRET between FVKRQW-tRNA Trp (Cy3) and tRNA Gln (Cy5). The in vitro ribosomal readthrough assay. Structural studies (Fernández, et al., 2014; Koh, et al., 198 2014; Muhs, et al., 2015; Murray, et al., 2016; Abeyrathne, et al., 2016) have shown that, prior to 199 polypeptide chain elongation, the cricket paralysis virus (CrPV) IRES structure occupies all three 200 tRNA binding sites (E, P, and A) on the 80S ribosome. We have recently demonstrated that the 201 first two cycles of peptide elongation proceed very slowly due to very low rates of pseudo-202 translocation and translocation, but that, following translocation of tripeptidyl-tRNA, subsequent 203 elongation cycles proceed more rapidly (Zhang, et al., 2016) . Based on these results we 204
constructed an assay to directly monitor readthrough of the sixth codon, when the faster elongation 205 rate is well established. For this purpose, we prepared the two CrPv IRES coding sequences, 206 STOP-IRES and Trp-IRES ( Figure 2 ). STOP-IRES contains the stop codon UGA at position 6 and 207 has a peptide coding sequence designed to give a high amount of readthrough, based on previous 208 studies showing that readthrough at the UGA stop codon proceeds in higher yields than at either 209 the UAA and UAG stop codons (Dabrowski, et al., 2015) and that such readthrough is further 210 increased by both a downstream CUA codon (encoding Leu) at positions +4 -+6 (Stiebler, et al., 211 2014; Loughran, et al., 2014) and an upstream AA sequence at positions -1 and -2 (Dabrowski, et 212 al., 2015) . In TRP-IRES UGA is replaced by UGG which is cognate to tRNA Trp , the most efficient 213 natural tRNA suppressor of the UGA codon (Blanchet, et al., 2014; Roy, et al., 2015) . Trp-IRES 214 encodes the octapeptide FKVRQWLM, which permits facile quantification of octapeptide 215 synthesis by 35 S-Met incorporation. 216
For the results reported below, we first prepared two POST5 translocation complexes, each 217 containing FKVRQ-tRNA Gln in the P-site, using ribosomes programmed with either STOP-IRES 218 or TRP-IRES. We then used the tRNA-Quant assay, which is rapid and precise, to determine the 219 amount of FKVRQWLM-tRNA Met formed on incubating each POST5 complex with a mixture of 220
Trp-tRNA Trp , Leu-tRNA Leu , [ 35 S]-Met-tRNA Met , elongation factors eEF1A and eEF2 and release 221 factors eRF1 and eRF3. We verified the validity of the tRNA-Quant assay by demonstrating that 222 it gives results that are very similar to those obtained with the PEP-Quant assay ( Figure S1 ), in 223 which, following base treatment, the amount of FKVRQWLM octapeptide is determined following 224 a TLE separation procedure (Zhang, et al., 2016; Youngman, et al., 2004) . Induction of readthrough by ataluren-like compounds. The NonSups ataluren, GJ072, and RTC 13 240 share similar structures, containing a central aromatic heterocycle having two or three substituents, 241 at least one of which is aromatic (Figure 1) . They also show similar S-shaped readthrough activity 242 saturation curves ( Figure 3B) , with EC 50 values between 0.17 -0.35 mM and plateau readthrough 243 efficiencies ranging from 0.10 -0.16 (Table 1) Our results suggest that aminoglycosides and ataluren-like compounds stimulate 297 readthrough by different mechanisms, AGs via binding to a single tight site on the ribosome and 298 ataluren-like compounds via weaker, multi-site binding. (Figures 3, S2 ; Table 1 ). The EC 50 values 299 found in intact cells differ considerably from those measured by tRNA-Quant, being much higher 300 for AGs (Bidou, et al., 2017; Baradaran-Heravi, et al., 2017) , and much lower for ataluren (Peltz, 301 et al., 2013; Roy, et al., 2016) , RTC13 (Du, et al., 2013) and GJ072 (Du, et al., 2013) . We attribute 302 these differences to the fact that positively charged aminoglycosides are taken up poorly into cells, 303 while uptake is favored for the hydrophobic ataluren-like molecules. Thus, vis-à-vis the culture 304 medium, intracellular concentration would be expected to be lower for AGs and higher for 305 ataluren, RTC13 and GJ072. Although the NonSups doxorubicin and negamycin have only modest 306 activities ( Figure 3 , Table 1 ) each of these compounds have potential interest for future 307 development. Doxorubicin has a relatively low EC 50 , is clinically approved for use in cancer 308 chemotherapy, and is the subject of ongoing efforts to identify doxorubicin congeners having 309 lower toxicity than doxorubicin itself (Kizek, et al., 2012; Edwardson, et al., 2015) . Negamycin 310 exhibits low acute toxicity and there are ongoing efforts to increase its readthrough activity via 311 structure -function studies (Taguchi, et al., 2017) . 312
A critical barrier to further development of NonSups that are clinically useful is the paucity 313 of information regarding the mechanisms by which they stimulate readthrough and misreading. 314
Aminoglycosides have well-characterized binding sites in both prokaryotic (Lin, et al., 2018) and 315 eukaryotic ribosomes (Garreau de Loubresse, et al., 2014) , proximal to the small subunit decoding 316 center, that have been linked to their promotion of misreading. Similarly, the functionally 317 important prokaryotic ribosome binding site of negamycin has also been identified within a 318 conserved small subunit rRNA region that is proximal to the decoding center (Lin, et al., 2018; 319 Spahn, et al., 2001) , and it is not unlikely that this site is also present in eukaryotic ribosomes. 320
However, nothing is known about the readthrough-inducing sites of action within the protein 321 synthesis apparatus of the ataluren-like NonSups ( Figure 3B ) or of doxorubicin. Indeed, it has even 322 been suggested that ataluren may not target the ribosome (Pibiri, et al., 2015) . Although 323 aminoglycosides have been the subject of detailed mechanism studies of their effects on 324 prokaryotic misreading (Liu, et al., 2014; Pape, et al., 2000; Gromadski and Rodnina, 2004; 325 Cochella, et al., 2006; Tsai, et al., 2013; Zhang, et al., 2018) 
